|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000033678 |
|
最近更新日期: Date of Last Refreshed on: |
2020-06-08 23:53:28 |
|
注册时间: Date of Registration: |
2020-06-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
健康管理APP项目对妇科癌症化疗患者疾病不确定性感知和身心健康的效果研究 |
|
Public title: |
A study regarding the effectiveness of health management application program on uncertainty in illness and physical and mental health of patients with gynecological cancer undergoing chemotherapy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妇科肿瘤在线支持项目APP与常规护理对中国妇科肿瘤化疗患者效果对比的多中心随机对照试验 |
|
Scientific title: |
A mobile application of gynecological cancer online-based support program versus routine care in the treatment of Chinese patients with gynecological cancer undergoing chemotherapy: a multicentre randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林慧聪 |
研究负责人: |
朱杰敏 |
|
Applicant: |
Huicong Lin |
Study leader: |
Jiemin Zhu |
|
申请注册联系人电话: Applicant telephone: |
+86 18170603387 |
研究负责人电话:
Study leader's |
+86 15960212649 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
+86 592-2189613 | |
|
申请注册联系人电子邮件: Applicant E-mail: |
lhcgyy@stu.xmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
Jieminzhu@xmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国福建省厦门市翔安区翔安南路厦门大学翔安校区 |
研究负责人通讯地址: |
中国福建省厦门市翔安区翔安南路厦门大学翔安校区爱礼楼222室 |
|
Applicant address: |
Xiang'an Campus of Xiamen University, Xiang'an Road South, Xiang'an District, Xiamen, Fujian, China |
Study leader's address: |
Room 222, Alice Lee Building, Xiang'an Campus of Xiamen University, Xiangan Road South, Xiang'an District, Xiamen, Fujian, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
厦门大学医学院 |
||
|
Applicant's institution: |
Xiamen University Medical College |
||
|
研究负责人所在单位: |
厦门大学医学院 |
||
|
Affiliation of the Leader: |
Xiamen University Medical College |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XDYX2019013 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门大学医学院伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of Xiamen University Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-12-18 00:00:00 | ||
|
伦理委员会联系人: |
陈彬彬 |
||
|
Contact Name of the ethic committee: |
Binbin Chen |
||
|
伦理委员会联系地址: |
中国福建省厦门市翔安区翔安南路厦门大学翔安校区爱礼楼208室 |
||
|
Contact Address of the ethic committee: |
Room 208, Alice lee Building, Xiang'an Campus of Xiamen University, Xiangan Road South, Xiang'an District, Xiamen, Fujian, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
厦门大学医学院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Xiamen University Medical College |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国福建省厦门市翔安区翔安南路厦门大学翔安校区爱礼楼222室 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
Room 222, Alice lee Building, Xiang'an Campus of Xiamen University, Xiangan Road South, Xiang'an District, Xiamen, Fujian, China |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(71974162) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (71974162) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
妇科癌症 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Gynecological cancer |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究通过开发健康管理APP,为妇科癌症患者提供相关知识、疾病不确定性管理、情绪照护和社会支持。探讨健康管理APP项目对妇科癌症化疗患者的疾病不确定性、症状困扰、生活质量和社会支持的影响,为今后的妇科癌症患者的健康管理提供参考依据。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
A new mobile health management application, called Gynecological Cancer Online-based Support (GOS) Program, will be developed in China to provide scientific cancer-related information and symptom management for patients with gynecological cancer undergoing chemotherapy, as well as support of society and emotion.The aim of this trial is to evaluate the effectiveness of the GOS program for Chinese patients with gynecological cancer undergoing chemotherapy in term of reducing illness uncertainty and symptom distress, and improving QoL and social support. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
(1)年满18岁; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1. Patients over 18 years old; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
(1)被诊断患有其他癌症; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients diagnosed with other cancers; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-02-01 00:00:00至 To 2022-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-02-01 00:00:00 至 To 2021-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
对陆续就医的患者进行区组随机化(block randomization),研究人员取区组长度(block size)为 4。每名患者都有可能分配到常规照护组(Control,C)或干预组(Intervention,I),每个区组4名患者的分配方案有6种(1-IICC,2-ICIC,3-ICCI,4-CIIC,5-CICI和6-CCII)。研究人员将使用Research Randomizer软件生成7套数字序列,每套序列包含六个随机排列的数字从1至6[112]。按照生成的数字输入代码,例如数字1代表输入 IICC。用此方法将168(7*6*4=168)患者随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Block randomization design (block size of 4) will be carried out on the patients who will hospitalize in succession. Each patient may be assigned to the control care group (Control, C) or intervention group (Intervention, I), and there are six allocation schemes. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
未可用 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA(not applicable) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集将通过纸质量表进行,而数据管理将通过社会科学统计软件包(the Statistical Package for the Social Sciences, SPSS)进行录入和分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection will be conducted through paper-based questionnaires, while data management will be input and analyzed through the Statistical Package for the Social Sciences (SPSS). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |